<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675946</url>
  </required_header>
  <id_info>
    <org_study_id>CGX1321-101</org_study_id>
    <secondary_id>MK3475-596</secondary_id>
    <nct_id>NCT02675946</nct_id>
  </id_info>
  <brief_title>CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)</brief_title>
  <official_title>A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curegenix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Curegenix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a&#xD;
      CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose&#xD;
      Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects&#xD;
      who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination&#xD;
      with pembrolizumab in colorectal tumors. Both phases are to evaluate safety,&#xD;
      pharmacokinetics, and clinical activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum&#xD;
      tolerated dose of CGX1321 when administered to subjects with advanced solid tumors.&#xD;
&#xD;
      The purpose of the Dose Expansion Phase, Roll-over Cohort and Phase 1b is to continue to&#xD;
      examine the safety and confirm the final Phase 2 dose of CGX1321 alone in subjects with&#xD;
      advanced GI tumors (Dose Expansion Phase) and evaluate the safety and tolerability of CGX1321&#xD;
      in combination with pembrolizumab (Phase 1b and Roll-over Cohort)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events and/or abnormal laboratory values that are related to treatment</measure>
    <time_frame>55 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGX1321 area under the curve</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGX1321 maximum or peak concentration</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGX1321 minimum or trough concentration</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGX1321 time to maximum concentration</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGX1321 half-life</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Solid Tumors</condition>
  <condition>GI Cancer</condition>
  <arm_group>
    <arm_group_label>CGX1321 alone and with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle&#xD;
Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle.&#xD;
Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).&#xD;
Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGX1321</intervention_name>
    <arm_group_label>CGX1321 alone and with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>CGX1321 alone and with pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-confirmed, locally advanced or metastatic solid tumors that have&#xD;
             relapsed or are refractory to or are not considered medically suitable to receive&#xD;
             standard of care treatment (Dose Escalation Phase)&#xD;
&#xD;
          -  Histologically-diagnosed, advanced Gl tumors that have relapsed or are refractory to&#xD;
             or are not considered medically suitable to receive standard of care treatment (Dose&#xD;
             Expansion Phase)&#xD;
&#xD;
          -  Histologically-diagnosed advanced colorectal tumors that have relapsed or are&#xD;
             refractory to or are not considered medically suitable to receive standard of care&#xD;
             treatment (Phase 1b)&#xD;
&#xD;
          -  Previous enrollment in Dose Escalation or Dose Expansion Phase with documented disease&#xD;
             progression while on single agent CGX1321 (Roll-over Cohort)&#xD;
&#xD;
          -  Radiologically measurable disease&#xD;
&#xD;
          -  Minimum life expectancy of 3 months&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Recovery from prior treatment-related toxicities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to a WNT inhibitor (except Roll-over cohort)&#xD;
&#xD;
          -  Prior exposure to an anti-PD-1, anti-PD-L1 or anti-PD-L2&#xD;
&#xD;
          -  Received previous therapy for malignancy within 21 days&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Radiotherapy within 2 weeks of first dose of study drug&#xD;
&#xD;
          -  Significant GI or variceal bleeding or subdural hematoma within 3 months of the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Known active central nervous system metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Currently receiving medications known to be inhibitors of CYP3A4/5. Subjects currently&#xD;
             receiving medications of known inducers of CYP3A4/5 or substrates of CYP2C8/9 and&#xD;
             CYP1A2 may be excluded.&#xD;
&#xD;
          -  Osteoporosis (T-score of less than -2.5 by DEXA scan)&#xD;
&#xD;
          -  Bone metastases with prior history of pathologic fracture, lytic lesions requiring an&#xD;
             orthopedic intervention, or not receiving bisphosphonates or denosumab&#xD;
&#xD;
          -  History of significant cardiac disease or uncontrolled hypertension&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Known active hepatitis A, B or C&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma that has&#xD;
             undergone potentially curative therapy or in situ cervical cancer&#xD;
&#xD;
          -  Active systemic infection requiring intravenous antibiotics within 2 weeks of&#xD;
             treatment start&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorders that would interfere with cooperation&#xD;
             with the requirements of the study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurie Rosenstein</last_name>
    <email>rosensteinl@us.curegenix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Montcalm</last_name>
      <phone>202-687-8974</phone>
      <email>jem257@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Ben Weinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jane Zorzi, RN</last_name>
      <phone>410-614-5818</phone>
      <email>jzorzi@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dung Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lynch, RN</last_name>
      <phone>617-643-0816</phone>
      <email>Lynch.Patricia2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Zhu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GI Research Line</last_name>
    </contact>
    <contact_backup>
      <phone>617-632-5960</phone>
    </contact_backup>
    <investigator>
      <last_name>Marios Giannakis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrance Lawrence</last_name>
      <phone>919-668-1861</phone>
      <email>Terrance.lawrence@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John Strickler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START (South Texas Accelerated Research Therapeutics, LLC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WNT inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

